(Hypertension. 1998;31:315.)
© 1998 American Heart Association, Inc.
Scientific Contributions |
From Department of Physiology and Biophysics and Center for Excellence in cared Cardiovascular and Renal Research, University of Mississippi Medical Center, Jackson, Miss.
Correspondence to Joey P. Granger, PhD, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State Streeet, Jackson, MS 39216-4505. E-mail JPG{at}fiona.umsmed.edu
| Abstract |
|---|
|
|
|---|
Key Words: nitric oxide blood flow pregnancy hypertension
Abbreviations: NO = nitric oxide PIH = pregnancy-induced hypertension MAP = mean arterial pressure L-NAME = N-nitro-L-arginine methyl ester L-NMMA = NG-monomethyl-L-arginine L-NNA = NG-nitro-L-arginine RBF = renal blood flow RPF = renal plasma flow RVR = renal vascular resistance GFR = glomerular filtration rate ANG II = angiotensin II ET = endothelin cAMP = cyclic adenosine monophosphate
| Introduction |
|---|
|
|
|---|
PIH, on the other hand, is characterized by increased systemic vascular resistance, contracted blood volume, enhanced sensitivity to vasopressor agents, altered renal hemodynamics, and vascular endothelial cell damage.11 Although the exact mechanism responsible for PIH is unclear, there is substantial evidence that maternal vascular endothelial cell dysfunction could be involved.12,13 Because NO is thought to play an important role in the control of arterial pressure and regional blood flow in nonpregnant animals, and since its levels have been reported to be elevated during pregnancy, decreased NO production has been proposed to contribute to the pathogenesis of PIH.10,14,15 Recent studies have indicated that chronic administration of NO synthesis inhibitors during mid to late gestation in rats leads to the development of hypertension and proteinuria that returned to prepregnant levels after delivery, a result suggesting a potential model that may mimic human preeclampsia.1618 However, the hemodynamic and regional blood flow alterations in this rat model of PIH have not been fully characterized.
The aim of this study was to determine the systemic hemodynamic and regional flow changes during normal pregnancy and in a rat model of PIH caused by chronic NO synthesis inhibition. To achieve these goals, we examined the systemic hemodynamics and regional blood flows using radiolabeled microspheres in conscious pregnant rats and in rats chronically treated with L-NAME for 1 week starting from mid-gestation.
| Methods |
|---|
|
|
|---|
The study was conducted on four groups of rats: virgin rats (n=6), pregnant rats (n=11), pregnant rats (n=10) that received the NO synthesis inhibitor L-NAME in drinking water for 7 prenatal days (days 13 to 19 gestation), and virgin rats that received L-NAME (n=6) in drinking water for one week before the experiment. L-NAME (Sigma Chemical Co.) was dissolved in distilled water at a dose of 50 mg/L ad libitum. On the basis of a preliminary study in our laboratory using this concentration of L-NAME in distilled water, each rat received approximately 1 mg of L-NAME per day. We also found that no difference in water intake was observed between virgin and pregnant rats until day 20 of pregnancy.16 A sperm-positive vaginal smear from females was considered day 1 of pregnancy. Pregnant rats were then housed individually in cages from the first day of pregnancy until the time of experimentation.
| Surgical Procedures |
|---|
|
|
|---|
| Microsphere Injection |
|---|
|
|
|---|
300,000 microspheres per coil. The coils were sealed with metal plugs at both ends, and radioactivity was determined by using a gamma counter (Series 1185). Each rat was prepared for microsphere injection in the conscious state by interposing the preloaded coil between the left ventricular catheter and a Gilford infusion pump and connecting the femoral catheter to a withdrawal pump of the same type. Microspheres were injected into the left ventricle and flushed with 0.6 mL of saline over a period of
20 seconds. The withdrawal pump was adjusted to collect a 1-mL blood sample from the femoral artery over a period of 90 seconds starting at the same time as the microsphere injection. | Cardiac Output and Regional Flow Measurement |
|---|
|
|
|---|
Cardiac output was calculated as follows:
![]() |
Tissue and organ flows were determined by the ratio of the number of microspheres in the tissue to the total number of injected microspheres times total cardiac output divided by the organ weight and expressed as mL/min/100 g of tissues.
| Statistical Analysis |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
Changes in Regional Hemodynamics in Virgin and Pregnant Rats in Response to Chronic NO Synthesis Inhibition
Fig 2 illustrates the renal hemodynamic changes in virgin and pregnant rats and in virgin and pregnant rats treated with L-NAME for 1 week. RBF in pregnant rats was 44% higher (14.59±3.92 versus 10.1±1.29 mL/min) and RVR was 12% lower (10.33±1.62 versus 11.73±1.70 mm Hg/mL/min) than in virgin rats. However, the renal hemodynamics in virgin and pregnant rats were not statistically different. In L-NAME-treated pregnant rats, RBF was significantly lower (6.06±0.83 versus 14.59±3.92 mL/min, P<.01) and RVR was significantly higher (28.25±3.61 versus 10.33±1.62 mm Hg/mL/min, P<.01) compared with pregnant controls. On the other hand, RBF in L-NAME-treated virgin rats was not statistically different from that in virgin controls despite the increase in RVR.
|
Table 1 shows the regional blood flow (mL/min/g) (Table 1A) and regional vascular resistance (mm Hg/mL/min/g tissue weight) (Table 1B) in different vascular beds (other than reproductive organs) in virgin and pregnant rats and in those chronically treated with L-NAME. Chronic inhibition of NO synthesis in virgin rats led to a significant (P<.01) decrease in pulmonary blood flow with no significant effects on blood flow to other vascular beds. However, in pregnant rats chronically treated with L-NAME, significant reductions in blood flow occurred in a wide variety of vascular beds, including heart, lungs, liver, and skeletal muscles (P<.05).
|
|
Table 2 shows the regional blood flow (mL/min) and vascular resistance (mm Hg/mL/min) in the uterus, ovary, and placenta in each group of rats. Pregnancy was associated with a 17-fold increase in uterine flow and a 22-fold decrease in uterine vascular resistance. Ovarian blood flow was also significantly higher and resistance was significantly lower in pregnant rats than in virgin rats and was not significantly altered in response to chronic NO synthesis inhibition in both groups. Uterine and placental flows in pregnant rats that were chronically treated with L-NAME were not statistically different from its values in the control pregnant group whether the data are expressed in total flow or flow per fetus.
|
| Discussion |
|---|
|
|
|---|
The data presented herein indicate that NO may play an important role in mediating the high-output, low-resistance, low-pressure state that is a hallmark of rat gestation. Nathan et al7 recently reported that in ganglion-blocked pregnant rats, inhibition of NO synthesis led to an increase in arterial pressure that was significantly greater in late pregnant rats than in nonpregnant rats. Molnar et al18 similarly observed a greater increase in blood pressure in pregnant rats given L-NAME chronically during late gestation than in virgin rats. In humans, a greater reduction in forearm flow was observed in late pregnant than in nonpregnant or early pregnant women during infusion of L-NMA into the brachial artery.21 Therefore, it appears that NO plays an important role in gestational dilation and decreased blood pressure during late stages of pregnancy but not during early or mid pregnancy. Other investigators, however, reported that the pressor responses to NO synthesis inhibition in late pregnant and nonpregnant rats were not statistically different.8,22 A major cause of the discrepancy between the results of these studies could be the doses used in the previous studies, which were high enough to cause marked hemodynamic changes in both virgin and pregnant rats.
Multiple mechanisms have been proposed to explain enhanced systemic vasoconstriction and accentuated arterial pressure response to NO synthesis blockade in pregnant rats. Edwards et al23 recently reported that long-term NO synthesis inhibition during mid to late gestation causes sustained hypertension and elevated levels of plasma ET-1. However, whether elevated ET-1 levels are a cause of increased blood pressure or a consequence of the endothelial injury caused by hypertension due to NO synthesis blockade is still unclear. Another possible mechanism is that NO synthesis blockade in pregnant rats unmasks of the vasoconstrictor effects of circulating ANG II, which is known to be elevated during pregnancy.7 Whether increased vascular smooth muscle tone during chronic NO synthesis inhibition in pregnant rats is due to a direct effect of reduced NO availability or indirectly due to enhanced activity of endogenous vasoconstrictors is still unclear and requires further investigation.
In addition to the peripheral vasoconstrictor effects of NO synthesis inhibition in pregnant rats, we observed a significant decrease in RBF and increase in RVR that were greater in pregnant than in virgin rats. NO has been previously shown to play an important role in the control of renal hemodynamics in the rat.24,25 A possible role for NO in mediating the gestational increases in renal blood flow is supported by studies by Danielson and Conrad,26 who reported that acute blockade of NO synthesis abrogates the renal vasodilation and hyperfiltration in pregnant rats. The same group of investigators,27 however, demonstrated that chronic blockade of NO (for 48 hours) failed to prevent the renal vasodilation during midgestation in rats mainly because of the compensatory increase in renal prostaglandins, since the vasodilation was prevented by meclofenamate. The difference between these results and the present study may be due to the gestational age when rats were examined or the dose, route, and duration of administration of L-NAME. Although the mechanism through which chronic NO inhibition increases renal vascular smooth muscle tone is unknown, it is unlikely that this effect is mediated through overexpression or increased sensitivity of endogenous vasoconstrictors, since we recently reported that L-NAME-treated pregnant rats exhibited the same degree of renal vascular response to exogenously administered ANG II as control pregnant rats.28 Therefore, it appears that NO may play an important role in mediating the gestational increases in RBF; further investigation is required to elucidate the mechanisms through which NO mediates renal vasodilation in pregnant rats.
We also observed a reduction in blood flow to other organs, including the heart, lungs, liver, and skeletal muscles, confirming the importance of NO in regulating regional blood flow during pregnancy. NO has been previously reported to play an important role in long-term regulation of regional blood flow in virgin rats.25 However, the state of NO production and its role in regulating regional blood flow during pregnancy have been studied mostly by using in vitro preparations. Using in situ blood-perfused mesenteric vessels, Chu and Beilin29 reported a comparable potentiation of basal perfusion pressure and vascular reactivity to L-NNA in late pregnant and non-pregnant rats. In isolated mesenteric vessels, the vasoconstrictor response to phenylephrine was attenuated in late pregnant rats compared with nonpregnant rats, and L-NAME30 or L-NNA31 caused a twofold potentiation of the vasoconstrictor response in both groups. In isolated hindlimb preparations, vascular reactivity to ANG II, but not to NE, was attenuated in late pregnant rats and was enhanced by LNMA to nonpregnant levels.32 Although these data support our observation that NO does not play a role in regulating mesenteric blood flow in pregnant rats, the pathological significance of NO in mediating the flow alterations to other vascular beds still needs to be investigated.
During the third trimester, a dramatic increase in blood flow to the uterus and placenta occurs to fulfill the nutritional needs of the rapidly growing fetus.6 Recent studies have presented evidence that NO production increases not only systemically during pregnancy but also in the uterine arteries in different animal species.10 Total nitrite production and cGMP levels are markedly elevated in rat uterine tissue during late gestation.33 Furthermore, calcium-dependent NO synthase activity has been shown to be elevated during pregnancy in guinea pig uterine arteries.34 A recent in vitro study has also demonstrated that the basal or activated endothelial-derived vasodilation is augmented in uterine arteries of late pregnant compared with nonpregnant rats, mainly because of enhanced release of NO.35 On the basis of these and other studies, it has been proposed that diminished NO synthesis in the uteroplacental circulation will cause a reduction in placental perfusion. Surprisingly, we did not observe a decrease in uterine or placental blood flow after chronic NO synthesis blockade in pregnant rats. In fact, uteroplacental flow tended to be higher in L-NAME-treated pregnant rats than in controls. This observation could be explained by different mechanisms. First, chronic L-NAME administration could induce the expression of inducible NO synthase, an enzyme that is known to produce a large amounts of NO and is less susceptible to inhibition by L-NAME.36,37 Second, since placental vessels lack the autoregulation, it is possible that the increased systemic arterial pressure in L-NAME-treated pregnant rats is transmitted to the placental circulation, overcoming the lack of vasodilation due to NO deficiency. Third, it is possible that a compensatory mechanism is present in the placenta to maintain placental perfusion by increasing synthesis (or enhancing the tissue sensitivity) of other vasodilators such as prostaglandins. This explanation is supported by recent studies demonstrating that pregnancy is associated with a twofold to threefold increase in uterine artery PG12 from both the endothelium and vascular smooth muscle. Furthermore, alterations in basal uterine cAMP production are related directly to alterations in PG12 production, and NO synthesis blockade does not alter either cAMP or PG12 production.38,39 Further regional flow studies using combined NO and prostaglandin blockade or servocontrolled uterine perfusion pressure may be needed to clarify this point.
In summary, we confirm our previous observations that chronic NO synthesis inhibition during mid to late gestation in rats is associated with a significantly greater increase in arterial pressure than in virgin rats. Chronic NO synthesis inhibition in pregnant rats was also associated with significant reduction in cardiac output and an increase in total peripheral resistance. L-NAME also caused significant reductions in blood flow to the kidneys, heart, lungs, liver, and skeletal muscles in pregnant rats. The changes in systemic and regional hemodynamics in response to NO synthesis inhibition in virgin rats either were not observed or were significantly less than in pregnant rats. The results of this study indicate that NO plays a role in mediating the alterations in systemic hemodynamics and regional flow in late pregnant rats.
| Acknowledgments |
|---|
Received September 17, 1997; first decision October 10, 1997; accepted October 22, 1997.
| References |
|---|
|
|
|---|
2. Christianson RE. Studies on blood pressure during pregnancy: influence of parity and age. Am J Obstet Gynecol. 1976; 125 : 509 513.[Medline] [Order article via Infotrieve]
3. Davison JM, Dunlop W. Renal hemodynamics and tubular function in normal human pregnancy. Kidney Int. 1980; 18 : 152 161.[Medline] [Order article via Infotrieve]
4. Magness RR, Zheng J. Maternal cardiovascular alterations during pregnancy. In P. D. Gluckman and MA Heymann, ed.: Pediatric and Perinatal Perspectives: The Scientific Basis. London: Arnold: 1996: 762 772.
5. Dowell RT, Kauer CD. Uteroplacental blood flow at rest and during exercise in late gestation conscious rats.
J Appl Physiol. 1993;
74
: 2079
2085.
6. Bruce NW. The distribution of blood flow to the reproductive organs of rats near term.
J Reprod Fertil. 1976;
46
: 359
362.
7. Nathan L, Cuevas J, Chaudhuri G. The role of nitric oxide in the altered vascular reactivity of pregnancy in the rat. Br J Pharmacol. 1995; 114 : 955 960.[Medline] [Order article via Infotrieve]
8. Molnar M, Hertelendy F. N o-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992; 166 : 1560 1567.[Medline] [Order article via Infotrieve]
9. Williams DJ, Vallance PJT, Neild GH, Spencer JAD, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol. 1997; 272 : H748 H752.[Medline] [Order article via Infotrieve]
10. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol. 1997; 272 : R441 R463.[Medline] [Order article via Infotrieve]
11. National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Consensus report. Am J Obstet Gynecol. 1990; 163 : 1689 1712.
12. De Groot CJM, Taylor RN. New insight into the etiology of preeclampsia. Ann Med. 1993; 25 : 243 249.[Medline] [Order article via Infotrieve]
13. Brown MA. The physiology of pre-eclampsia. Clin Exper Pharmacol Physiol. 1995; 22 : 781 791.[Medline] [Order article via Infotrieve]
14. Morris NH, Eaton BM, Dekker G. Nitric Oxide, the endothelium, pregnancy and pre-eclampsia. Br J Obstet Gynecol. 1996; 103 : 4 15.[Medline] [Order article via Infotrieve]
15. Friedman SA, Lubarsky SL, Ahokas RA, Nova A, Sibai BM. Pre-eclampsia and related disorders: clinical aspects and relevance of endothelin and nitric oxide. Clin Perinatol. 1995; 2 : 343 355.
16. Novak J, Cockrell K, Kassab S, Reckelhoff JF, Granger JP. Chronic nitric oxide synthesis inhibition during pregnancy increases thromboxane excretion in rats. FASEB J. 1997; 11 : A78 .
17. Baylis C, Engels K. Adverse interactions between pregnancy and a new model of systemic hypertension produced by chronic blockade of endothelial derived relaxing factor (EDRF) in the rat. Clin Exp Hypertens. 1992; B11 : 117 129.
18. Molnar M, Suto T, Toth T, Hertelendy F. Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol. 1994; 170 : 1458 1466.[Medline] [Order article via Infotrieve]
19. Henry RT, Casto R. Simple and inexpensive delivery of halogenated inhalation anesthetics to rodents. Am J Physiol. 1989; 257 : R668 R671.[Medline] [Order article via Infotrieve]
20. Stanek KA, Smith TL, Murphy WR, Coleman TG. Hemodynamic disturbances in the rat as a function of the number of microspheres injected. Am J Physiol. 1983; 245 : H920 H923.[Medline] [Order article via Infotrieve]
21. Williams DJ, Vallance PJT, Neild GH, Spencer JAD, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol. 1997; 272 : H748 H752.[Medline] [Order article via Infotrieve]
22. Umans JG, Linheimer MD, Barron WM. Pressor effect of endothelium-derived relaxing factor inhibition in conscious virgin and gravid rats. Am J Physiol. 1990; 259 : F293 F296.[Medline] [Order article via Infotrieve]
23. Edwards DL, Arora CP, Bui DT, Castro LC. Long-term nitric oxide blockade in the pregnant rat: effects on blood pressure and plasma levels of endothelin-1. Am J Obstet Gynecol. 1996; 175 : 484 488.[Medline] [Order article via Infotrieve]
24. Baylis C, Harton P, Engels K. Endothelium-derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol. 1990; 1 : 875 881.[Abstract]
25. Huang M, Manning D, LeBlanc MH, Hester RL. Overall hemodynamic studies after the chronic inhibition of endothelial-derived nitric oxide in rats. Am J Hypertens. 1995; 8 : 358 364.[Medline] [Order article via Infotrieve]
26. Danielson LA, Conrad KP. Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J Clin Invest. 1995; 96 : 482 490.[Medline] [Order article via Infotrieve]
27. Danielson LA, Conrad KP. Prostaglandins maintain renal vasodilation and hyperfiltration during chronic nitric oxide synthase blockade in conscious pregnant rats.
Circ Res. 1996;
79
: 1161
1166.
28. Novak J, Reckelhoff JF, Bumgarner L, Cockrell K, Kassab S, Granger JP. Role of nitric oxide in mediating the reduced sensitivity of the renal circulation to angiotensin II in rats.
Hypertension. 1997;
30
: 580
584.
29. Chu ZM, Beilin LJ. Mechanisms of vasodilation in pregnancy: studies of the role of prostaglandins and nitric oxide in changes of vascular reactivity in the in situ blood perfused mesentry of pregnant rats. Br J Pharmacol. 1993; 109 : 322 329.[Medline] [Order article via Infotrieve]
30. Davidge ST, McLaughlin MK. Endogenous modulation of the blunted adrenergic response in resistance-sized mesentric arteries from the pregnant rat. Am J Obstet Gynecol. 1992; 167 : 1691 1698.[Medline] [Order article via Infotrieve]
31. Pascoal IF, Lindheimer MD, Nalbantian-Brandt C, Umans GJ. Con traction and endothelium-dependent relaxation in mesentric microvessels from pregnant rats. Am J Physiol. 1995; 269 : H1899 H1904.[Medline] [Order article via Infotrieve]
32. Ahokas RA, Sibai BM. Endothelium-derived relaxing factor inhibition augments vascular angiotensin II reactivity in the pregnant rat hindlimb. Am J Obstet Gynecol. 1992; 167 : 1053 1058.[Medline] [Order article via Infotrieve]
33. Yallampalli C, Byam-Smith M, Nelson SO, Garfield RE. Steroid hormones modulate the production of nitric oxide and cGMP in the rat uterus.
Endocrinology. 1994;
134
: 1971
1974.
34. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Chades IG, Moncada S. Induction of calcium-dependent nitric oxide synthase by sex hormones.
Proc Natl Acad Sci U S A. 1994;
91
: 5212
5216.
35. Ni Y, Meyer M, Osol G. Gestation increases nitric oxide-mediated vasodilation in rat uterine arteries. Am J Obstet Gynecol. 1997; 176 : 856 864.[Medline] [Order article via Infotrieve]
36. Furfine ES, Harmon MF, Paith JE, Carvet EP. Selective inhibition of constitutive nitric oxide synthase by L-nitroarginine. Biochemistry. 1993; 32 : 8512 8517.[Medline] [Order article via Infotrieve]
37. Lyall F, Young A, Greer IA. Nitric oxide concentrations are increased in the fetoplacental circulation in preeclampsia. Am J Obstet Gynecol. 1995; 173 : 714 718.[Medline] [Order article via Infotrieve]
38. Magness RR, Shaw CE, Phernetton TM, Zheng J, Bird IM. Endothelial vasodilator production by uterine and systemic arteries. II. Pregnancy effects on NO synthase expression. Am J Physiol. 1997; 272 : H1730 H1740.[Medline] [Order article via Infotrieve]
39. Magness RR, Rosenfeld CR, Hassan A, Shaul PW. Endothelial vasodilator production by uterine and systemic arteries: effects of ANG II on PGI2 and NO in pregnancy. Am J Physiol. 1997; 272 : H1730 H1740.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Sholook, J. S. Gilbert, M. H. Sedeek, M. Huang, R. L. Hester, and J. P. Granger Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2080 - H2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Huang, Y. Zhou, V. T. Raju, J. Du, H.-H. Chang, C.-Y. Wang, M. W. Brands, J. R. Falck, and M.-H. Wang Renal 20-HETE inhibition attenuates changes in renal hemodynamics induced by L-NAME treatment in pregnant rats Am J Physiol Renal Physiol, November 1, 2005; 289(5): F1116 - F1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cherla and E. A. Jaimes Role of L-Arginine in the Pathogenesis and Treatment of Renal Disease J. Nutr., October 1, 2004; 134(10): 2801S - 2806S. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Alexander, M. T. Llinas, W. C. Kruckeberg, and J. P. Granger L-Arginine Attenuates Hypertension in Pregnant Rats With Reduced Uterine Perfusion Pressure Hypertension, April 1, 2004; 43(4): 832 - 836. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Sedeek, M. T. Llinas, H. Drummond, L. Fortepiani, S. R. Abram, B. T. Alexander, J. F. Reckelhoff, and J. P. Granger Role of Reactive Oxygen Species in Endothelin-Induced Hypertension Hypertension, October 1, 2003; 42(4): 806 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Beausejour, K. Auger, J. St-Louis, and M. Brochu High-sodium intake prevents pregnancy-induced decrease of blood pressure in the rat Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H375 - H383. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Wang, B. A. Zand, A. Nasjletti, and M. Laniado-Schwartzman Renal 20-hydroxyeicosatetraenoic acid synthesis during pregnancy Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2002; 282(2): R383 - R389. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Abram, B. T. Alexander, W. A. Bennett, and J. P. Granger Role of neuronal nitric oxide synthase in mediating renal hemodynamic changes during pregnancy Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1390 - R1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Brooks, K. A. Clow, L. S. Welch, and G. D. Giraud Does nitric oxide contribute to the basal vasodilation of pregnancy in conscious rabbits? Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1624 - R1632. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Alexander, K. L. Cockrell, A. N. Rinewalt, J. N. Herrington, and J. P. Granger Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1388 - R1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Cadnapaphornchai, M. Ohara, K. G. Morris Jr., M. Knotek, B. Rogachev, T. Ladtkow, E. P. Carter, and R. W. Schrier Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy Am J Physiol Renal Physiol, April 1, 2001; 280(4): F592 - F598. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Alexander, S. E. Kassab, M. T. Miller, S. R. Abram, J. F. Reckelhoff, W. A. Bennett, and J. P. Granger Reduced Uterine Perfusion Pressure During Pregnancy in the Rat Is Associated With Increases in Arterial Pressure and Changes in Renal Nitric Oxide Hypertension, April 1, 2001; 37(4): 1191 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Murphy, J. B. Fleming, K. L. Cockrell, J. P. Granger, and R. A. Khalil [Ca2+]i signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2001; 280(1): R87 - R99. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jablonka-Shariff, R. Basuray, and L. M. Olson Inhibitors of Nitric Oxide Synthase Influence Oocyte Maturation in Rats Reproductive Sciences, March 1, 1999; 6(2): 95 - 101. [Abstract] [PDF] |
||||
![]() |
B. T. Alexander, M. T. Miller, S. Kassab, J. Novak, J. F. Reckelhoff, W. C. Kruckeberg, and J. P. Granger Differential Expression of Renal Nitric Oxide Synthase Isoforms During Pregnancy in Rats Hypertension, January 1, 1999; 33(1): 435 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zatz and C. Baylis Chronic Nitric Oxide Inhibition Model Six Years On Hypertension, December 1, 1998; 32(6): 958 - 964. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |